P

Pfizer

Makes cancer drugs, vaccines and other medicines

Director, QSEO AI Transformation Lead

Full-TimePosted on 10/22/2026Deadline 11/5/26
$176.6k - $294.3k/yr+ 20% bonus target + Share-based long-term incentive
Senior, Expert
Bachelor's, Master's, PhD
Collegeville, PA, USA
HybridHybrid work; periodic meetings outside standard hours and occasional business travel may be required.
Biology & BiotechRegulatory & Quality (Life Sciences)
No H1B Sponsorship

About the job

Requirements
  • A bachelor's degree in a scientific, engineering, technology, data, quality or related discipline with at least eight years of relevant experience; or a master's degree with at least seven years of relevant experience; or a doctoral degree with at least five years of relevant experience.
  • Significant experience in pharmaceutical quality, manufacturing, regulatory compliance, Digital quality or another regulated environment.
  • Demonstrated expertise in GxP quality systems, risk management, computerized systems, Digital governance, AI governance or related disciplines.
  • Experience applying quality and risk-management principles across the life cycle of Digital, computerized or AI-enabled solutions.
  • Demonstrated experience leading complex, cross-functional initiatives in a global, highly matrixed organization.
  • Experience supporting regulatory inspections, internal audits or inspection-readiness activities as a subject-matter expert.
  • Demonstrated ability to exercise independent judgment and develop recommendations for highly complex and ambiguous issues.
  • Proven ability to influence senior leaders and drive alignment across Quality, Digital, Operations and business stakeholders without direct authority.
  • Strong written and verbal communication skills, including the ability to translate technical and regulatory issues into clear business and risk insights.
  • Working knowledge of artificial intelligence and machine-learning concepts, including model life cycle, data quality, performance monitoring, drift, explainability and human oversight.
  • Ability to evaluate multiple complex and concurrent inputs, exercise sound judgment and develop clear, actionable recommendations.
  • Ability to manage competing priorities and operate effectively in a complex, matrixed and globally distributed environment.
  • Candidates must be authorized to be employed in the United States by any employer and have permanent work authorization in the United States.
Responsibilities
  • Provide strategic leadership for QSEO AI transformation, governance and quality oversight across the PGS AI portfolio.
  • Translate the Native-AI vision into governance strategies, quality approaches and implementation plans that accelerate responsible AI adoption.
  • Advise senior leaders on AI opportunities, regulatory expectations, GxP risks, investment priorities and deployment considerations.
  • Establish and maintain risk-based quality oversight for Digital and federated AI solutions throughout the AI life cycle.
  • Lead the AI Quality Review Board and GxP AI Steering Committee, driving effective decisions, escalation and closure of agreed actions.
  • Establish portfolio-level approaches for AI audit and inspection readiness, identifying systemic risks and recommending corrective or preventive actions.
  • Monitor emerging AI regulations, standards and industry practices and translate their implications into practical internal requirements and recommendations.
  • Represent QSEO in enterprise AI governance forums and lead resolution of actions arising from the PGS AI Council.
  • Provide strategic leadership for maintenance, adoption and continuous improvement of the AI life-cycle process.
  • Simplify AI governance and delivery processes while maintaining appropriate quality, compliance and risk controls.
  • Establish expectations for accurate AI inventory management and influence an integrated enterprise approach to AI life-cycle visibility.
  • Define and advance a portfolio-level approach for monitoring the health, performance and control status of GxP-relevant AI solutions.
  • Provide strategic direction for PGS AI governance and quality tools, including AIRIF and AIQAS, and their alignment with the PGS platform strategy.
  • Establish and guide the QSEO AI community of practice, partnering with PGS GxP AI ambassadors and relevant PGS, Digital and Research & Development organizations.
  • Develop portfolio metrics and insights that provide senior leaders with visibility into AI adoption, quality, compliance, risk and value.
  • Lead QSEO AI-related IMEx reporting, resource visibility, risk assessment and escalation.
  • Periodic participation in meetings outside standard working hours may be required to support global stakeholders.
  • Occasional business travel may be required based on portfolio and program needs.
Desired Qualifications
  • Advanced degree in a scientific, engineering, data, technology, regulatory or quality discipline.
  • Experience developing or implementing governance for AI or machine-learning solutions in a GxP environment.
  • Familiarity with applicable AI, quality and risk-management regulations, standards and guidance.
  • Experience leading senior governance or multidisciplinary decision-making forums.
  • Experience establishing portfolio-level monitoring, inspection-readiness or risk-reporting approaches.
  • Quality, auditing, risk-management, Digital, data or AI-related certification.
  • Experience applying IMEx, Lean, Six Sigma or comparable process-improvement methods.
  • Experience with portfolio management, governance tools, value reporting or AI inventory management.
  • Ability to influence and collaborate with peers, develop and coach others, and oversee and guide colleagues' work to achieve outcomes and business impact.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Oct 22nd, 2026
Pfizer's 5.7% yield signals risk: dividends took 108% of free cash flow vs Merck's 66%

Merck's dividend looks safer than Pfizer's, despite Pfizer's higher yield, according to a 24/7 Wall St. comparison. Pfizer yields about 5.7% against Merck's 2.2%. In 2025, Pfizer's dividends used 108% of free cash flow, while Merck's used 66%. In the first half of 2026, Merck's free cash flow covered 174% of its payout; Pfizer's covered about 51%. Merck has raised its quarterly dividend 39% since 2020, to $0.85. Pfizer's rose 13% and has been flat at $0.43 since January 2025. Pfizer is cheaper, at about 10 times 2026 earnings against Merck's 17. Pfizer targets a return to growth from 2029, while Merck's newer drugs are already selling.

Yahoo Finance
Oct 21st, 2026
Pfizer announces layoffs at Rocky Mount and Sanford sites, but gives no numbers

Pfizer has announced layoffs at its Rocky Mount and Sanford facilities in North Carolina, as part of a push to improve efficiency. It told employees of the cuts on Tuesday but did not say how many jobs will go, when, or in which departments. Rocky Mount makes sterile injectables, while Sanford focuses on vaccines and advanced biologics, including gene therapies. "Headcount reductions are a part of this initiative," Pfizer said, adding that it will give affected staff support services. "If indeed this happens, it's going to affect those families," said David Farris, president and chief executive officer of the Rocky Mount Area Chamber of Commerce. The impact on local economies, he said, depends on the number laid off. As of Wednesday afternoon, no Worker Adjustment and Retraining Notification (WARN) notice had been filed with the state.

Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

Yahoo Finance
Oct 14th, 2026
Pfizer's 6% dividend pays investors to wait as oncology pipeline drives growth beyond COVID-19

Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.